HER2 insertion YVMA mutant lung cancer: Long natural history and response to afatinib Journal Article
| Authors: | Li, B. T.; Lee, A.; O'toole, S.; Cooper, W.; Yu, B.; Chaft, J. E.; Arcila, M. E.; Kris, M. G.; Pavlakis, N. |
| Article Title: | HER2 insertion YVMA mutant lung cancer: Long natural history and response to afatinib |
| Abstract: | Human epidermal growth factor 2 (HER2, ERBB2) mutations in lung cancers are oncogenic drivers that respond to HER2 targeted therapies. Little is known about the sensitivity of subtypes of HER2 mutant lung cancers to targeted agents. We present a patient with HER2 mutant lung cancer with a 12 base pair insertion YVMA (p.A775_G776insYVMA), who had a long natural history and durable partial response to afatinib. We demonstrate that afatinib has activity in patients with HER2 mutant lung cancers with exon 20 YVMA insertions, the most common variant. © 2015 Elsevier Ireland Ltd. |
| Keywords: | immunohistochemistry; adult; middle aged; mutation; case report; bevacizumab; cancer combination chemotherapy; drug withdrawal; gemcitabine; lymph node metastasis; mass spectrometry; carboplatin; epidermal growth factor receptor 2; lung cancer; docetaxel; gastrointestinal toxicity; disease severity; lung adenocarcinoma; fluorescence in situ hybridization; spinal cord compression; targeted therapy; pemetrexed; pertuzumab; lung parenchyma; spinal cord decompression; afatinib; dacomitinib; human epidermal growth factor receptor 2 (her2); human; male; priority journal; article |
| Journal Title: | Lung Cancer |
| Volume: | 90 |
| Issue: | 3 |
| ISSN: | 0169-5002 |
| Publisher: | Elsevier Ireland Ltd. |
| Date Published: | 2015-12-01 |
| Start Page: | 617 |
| End Page: | 619 |
| Language: | English |
| DOI: | 10.1016/j.lungcan.2015.10.025 |
| PROVIDER: | scopus |
| PUBMED: | 26559459 |
| PMCID: | PMC4724317 |
| DOI/URL: | |
| Notes: | Article -- Export Date: 7 January 2016 -- 617 -- Source: Scopus |
Altmetric
Citation Impact
BMJ Impact Analytics
Related MSK Work